Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
October 09, 2025 07:00 ET | Source: Axsome Therapeutics, Inc. NEW YORK,…
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE…
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging…
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
